Skip to content

Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder

Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05517304
Acronym
VNS in PTSD
Enrollment
80
Registered
2022-08-26
Start date
2022-10-01
Completion date
2027-11-10
Last updated
2026-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Disorders, Post-Traumatic

Keywords

Stress Disorders, Post-Traumatic, PTSD, Vagus Nerve

Brief summary

This study effects the effects of transcutaneous cervical vagal nerve stimulation (tcVNS) or a sham control on brain, physiology, and PTSD symptoms in Veterans with posttraumatic stress disorder (PTSD). Veterans undergo brain imaging and physiological measures in conjunction with traumatic scripts before and after three months of twice daily treatment with tcVNS or sham stimulation at home.

Detailed description

Description: This study assesses brain function measured with High Resolution Positron Emission Tomography (HR-PET) during exposure to stressful traumatic scripts paired with tcVNS or sham stimulation, with secondary measures of blood inflammatory biomarkers, and sympathetic function. Participants then undergo three months of twice daily home treatment with repeat measures. Drug/Device Handling: \[O-15\] radiolabeled water has a half-life of 110 seconds and is made on site at the Emory Center for Systems Imaging (CSI). Dr. Bremner holds the Investigational New Drug (IND) approval for use of radiolabeled water at Emory University. The investigators have performed hundreds of studies in human subjects at Emory and there have been no adverse events or untoward effects to date. tcVNS with the GammaCore device is approved by the Emory IRB for a recently completed study in PTSD and others in progress for Opioid Use Disorder and was shown to be well tolerated and there have been no adverse events or untoward effects with the device. The FDA granted Breakthrough Device Designation for PTSD for the gammaCore tcVNS device based on the investigators' studies. Devices are blinded by ElectroCore and the devices and information are kept by the Data Manager under double lock and key. Device records are kept by the Data Manager and stored on Redcap or secured research drives. Devices are given to the study team along with a device schedule under direct supervision from the investigator.

Interventions

DEVICEtcVNS

Active stimulation with transcutaneous Vagal Nerve Stimulation (tcVNS)

DEVICESham

Sham stimulation

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Sham stimulation comparison

Intervention model description

tcVNS versus sham stimulation

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Veterans between the ages of 18 and 75 will be included with a diagnosis of PTSD based on DSM-5 criteria

Exclusion criteria

Subjects will be excluded with: * a history of mild traumatic brain injury (mTBI) based on VA Criteria * moderate or greater TBI * positive pregnancy test * meningitis or other neurological disorder * alcohol or substance abuse use disorder based on DSM-5 criteria within the past 12 months * current or lifetime history of schizophrenia, schizoaffective disorder, bipolar I disorder, anorexia nervosa or bulimia, based on DSM-5 * active suicidal ideation with a plan * a history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness that would preclude participation based on clinical judgment of the PI * active opiate or benzodiazepine treatment * history of structural abnormality on brain MRI or CT if one has been performed in the past

Design outcomes

Primary

MeasureTime frameDescription
Change in PTSD symptomsBaseline to three monthsChange in PTSD symptoms measured with the Clinician Administered PTSD Scale (CAPS) and PTSD Checklist (PCL) in tcVNS versus sham conditions
Brain ActivationBaselineChange in brain activation in insula measured with PET in response to trauma scripts with VNS compared to sham

Secondary

MeasureTime frameDescription
Sympathetic functionBaselineChange in pre-ejection period (PEP) during traumatic scripts with VNS compared to sham. PEP is the time from ventricular contraction to aortic valve opening and is a measure of cardiac sympathetic tone
Interleukin-6BaselineChange in interleukin 6 concentration in blood in response to traumatic scripts with stimulation with VNS versus stimulation with sham

Countries

United States

Contacts

CONTACTDoug J Bremner, MD
James.Bremner@va.gov(404) 712-9569
PRINCIPAL_INVESTIGATORDoug J Bremner, MD

Atlanta VA Medical and Rehab Center, Decatur, GA

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026